Slide 1: Presentation to Investors August, 2010
CONFIDENTIAL Presentation to Investors August, 2010
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its offic
Slide 3: Mission Statement
Mission Statement BioScrip, Inc. is a national provider of specialty pharmacy and home care products and services that partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivery of cost-effective access to p
Slide 4: BioScrip is an Integrated Solution
BioScrip is an Integrated Solution 3 Central Mail- Order Facilities 33 Community Pharmacies + 33 Nursing Locations 61 Specialized Infusion Pharmacies 27 State Presence + District of Columbia 1,000+ Managed Care Relationships 125K+ Patient Census BioScrip Affiliated Pharmacies BioScrip
Slide 5: BioScrip's Strategy
BioScrip's Strategy Geographic & margin expansion Build clinical leadership across all technologies: infusion, oral, injectibles Leverage comprehensive nursing capability for chronically ill Build customized care management programs Cross-sell all services on a national level Leverage broad relation
Slide 6: BioScrip Value Proposition
BioScrip Value Proposition Physicians BioScrip Infusion Home Health Education Delivery Administration Pharmacy Services Home Care Nursing $ Referrals $ Drugs $ Patients Payors Enrollment In-Network Drug Benefit Healthcare Services Medical Benefit Drug Benefit Medical Benefit Drug Dispensing Pharmace
Slide 7: Expertise as a Valued Partner
Expertise as a Valued Partner Physicians REACH Payors Patients Pharma Clinical support and plan of care coordination National + local presence Single source solution for medical services and supplies Clinical support and plan of care coordination Broad service portfolio Broad service portfolio Deep
Slide 8: BioScrip Operating Services Model
BioScrip Operating Services Model Pharmacy Services Home Infusion Infusion at home Infusion compounding Specialized equipment High-tech infusion Mail-Delivered Products Custom dosing Special inventory management Ambulatory Infusion Contract clinical and business management High-tech infusion nursing
Slide 9: BioScrip is Clinically Focused
BioScrip is Clinically Focused Minimum Clinical Standards BioScrip Technical Program Enhanced Rx Management Solutions BioScrip CareTM Disease-specific and co-morbidity clinical management solutions Maximize the patient experience Consistency in clinical care delivery Optimized tools for targeted int
Slide 10: Loyal Prescribing Physician Relationships
Loyal Prescribing Physician Relationships Active Referring Physicians Nationwide Maintains active relationships with more than 100,000 physician prescribers across various therapy segments and geographies Substantially all of BioScrip's commercial payor revenues are in- network Compelling clinical e
Slide 11: 1000+ Pharma and Managed Care Relationships
1000 + Pharma and Managed Care Relationships BioScrip Relationships Employers and coalitions National health plans Regional health plans Veterans administration Specialty pharmacy providers Integrated delivery networks Government Medicaid Medicare Hospitals PBM's Medical groups Oncology networks Pat
Slide 12: Favorable Payor Profile
Favorable Payor Profile Revenue Payor Mix 2nd Quarter BioScrip
Slide 13: Integration Update & Goals
Integration Update & Goals Continue Focus on Core High- Value Therapies Sales & Marketing at both the Local and Regional Level Continue Acquisition Program Local Clinical Model Emphasizing Custom Care Management Leverage Relationships with National MCOs Total parenteral and enteral nutrition therapi
Slide 14: Industry Dynamics
Industry Dynamics Infusion Therapy Savings per Episode1 Historical and Projected U.S. Population Age 65+1 Average per Capita Spend on Chronic Conditions2 Historical and Projected Pharmaceutical Spend2
Slide 15: Financial Summary
Financial Summary
Slide 16: 2010 Consolidated Results
2010 Consolidated Results Adjusted EBITDA is earnings before interest, taxes, depreciation, amortization, stock based compensation and transaction related expenses. Q2 2010 pro forma numbers exclude transaction related expenses of $1.1 million in 2010 and a normalized tax rate of 41% for 2009. YTD 2
Slide 17: Segment Results
Segment Results pio&pscrip (00's) Three Months Ended ‘Six Months Ended June 20, June 20, 2070 200 Results of Operations: Revenue: InfusioniHiome Health Services $106,675 Pharmacy Services 305,355 Total $412,030 ‘Adjusted EBITDA by Segment before corporate overhead: InfusioniHome Health Services S 13
Slide 18: 2nd Quarter 2010 Free Cash Flow
2nd Quarter 2010 Free Cash Flow
Slide 19: Balance Sheet - Update (condensed)
Balance Sheet - Update (condensed)
Slide 20: 2010 Sales Bridge-Pharmacy Services
2010 Sales Bridge-Pharmacy Services 3rd quarter base business is expected to increase 2.7% over June run rate due to historical trends, patient census and drug inflation. 4th quarter base business is expected to increase 3.1% over 3rd quarter base business run rate due to historical trends, patient
Slide 21: 2010 Sales Bridge-Infusion/Home Health
2010 Sales Bridge-Infusion/Home Health 3rd quarter base business is expected to increase 5.0% over June run rate due to historical trends, patient census and drug inflation. 4th quarter base business is expected to increase 5.0% over 3rd quarter base business run rate due to historical trends, patie
Slide 22: 2010 Sales Bridge-Combined
2010 Sales Bridge-Combined 3rd quarter base business is expected to increase 3.1% over June run rate due to historical trends, patient census and drug inflation. 4th quarter base business is expected to increase 3.7% over 3rd quarter base business run rate due to historical trends, patient census an